Trade Names:
Synonyms:
Status: Approved (2014)
Entry Type: Antibody
Molecule Category: UNKNOWN
ATC: L04AC11
UNII: T4H8FMA7IM

Pharmacology

Action Mechanism of Action Reference
ANTAGONIST Interleukin-6 inhibitor FDA

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Castleman Disease 4 D005871 ClinicalTrials
Severe Acute Respiratory Syndrome 3 D045169 ClinicalTrials
Multiple Myeloma 3 D009101 ClinicalTrials
Myelodysplastic Syndromes 2 D009190 ClinicalTrials
Prostatic Neoplasms 2 D011471 ClinicalTrials
Kidney Neoplasms 2 D007680 ClinicalTrials
Prostatic Neoplasms, Castration-Resistant 2 D064129 ClinicalTrials
Prostatic Neoplasms 2 D011471 ClinicalTrials
Carcinoma, Renal Cell 1 D002292 ClinicalTrials
Schizophrenia 1 D012559 ClinicalTrials
Paraproteinemias 1 D010265 ClinicalTrials
Diabetes Mellitus, Type 1 0 D003922 ClinicalTrials

Adverse Reactions

System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
14.35
Injury, poisoning and procedural complications
10.97
Vascular disorders
8.44
Nervous system disorders
7.17
Eye disorders
6.33
Gastrointestinal disorders
6.33
Respiratory, thoracic and mediastinal disorders
5.49
Skin and subcutaneous tissue disorders
5.06
Blood and lymphatic system disorders
4.64
Musculoskeletal and connective tissue disorders
4.22
Cardiac disorders
3.8
Immune system disorders
3.8
Infections and infestations
3.8
Investigations
3.38
Metabolism and nutrition disorders
2.95
Psychiatric disorders
2.95
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
2.11
Renal and urinary disorders
2.11

Cross References

Resources Reference
CAS NUMBER 541502-14-1
ChEMBL CHEMBL1743070
FDA SRS T4H8FMA7IM
Guide to Pharmacology 7396